New User Account Set Up

If you do not have an account with the Digest, please click on "Submit to the Digest." By logging in with your UCLA Login ID (formerly known as BOL Login), a new account will automatically be generated. If you experience any difficulties, please send an email to our help desk:


If you have any questions or concerns, please email our help desk/support team: We are more than happy to address any questions or concerns regarding the Weekly Message Digest system you may have.

How do I subscribe?

If you have a mednet email account (, you should already be subscribed.

If you do not have a mednet email account or you are not receiving the Digest, please send an email to and we will add you to our list.

A5386: New Phase I clinical trial for HIV+ individuals who are Undetectable

This study is looking for people with HIV who are taking HIV treatment and whose viral load is undetectable. The study will see if an experimental product called IL-15 given alone or in combination with two antibodies directed against HIV, called broadly neutralizing antibodies (bNAbs), is safe and leads to control of HIV. Half of the participants will receive 8 doses of IL-15 given every 3 weeks and half will receive 8 doses of IL-15 given every 3 weeks plus the bNAbs. After receiving these products, participants will temporarily stop taking their HIV treatment and will be monitored closely to see if their HIV is controlled without HIV treatment.  


Key eligibility criteria:

  • Age 18 to 65 years old
  • HIV positive
  • On continuous HIV treatment (antiretroviral therapy) for at least 96 weeks
  • Undetectable HIV viral load for at least 96 weeks
  • CD4 cell count more than 500
  • No active (untreated) hepatitis B or C infection
  • Not pregnant or breastfeeding


For more information contact the UCLA study team at (310) 843-2015 or

Posting Information
This posting expired on September 16, 2022.
Posting Attachment: Download Attachment

Share this posting on social media!